Showing 1 - 10 of 1,436
There has been much recent debate in the health economics literature as to the (near) equivalence of cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). The aim of this paper is to demonstrate that whether such a (near) equivalence exists depends on whether one defines economic...
Persistent link: https://www.econbiz.de/10005448995
The recent rush of enthusiasm for public investment in comparative effectiveness research (CER) in the US has focussed attention on these public investments. However, little attention has been given to how changing public investment in CER may affect private manufacturers' incentives for CER,...
Persistent link: https://www.econbiz.de/10010569822
Objective: To conduct a Bayesian value-of-information analysis of the cost effectiveness of pentoxifylline (vs placebo) as an adjunct to compression for venous leg ulcers. Methods: A probabilistic Markov model was developed to estimate mean clinical benefits and costs associated with oral...
Persistent link: https://www.econbiz.de/10005590300
Healthcare expenditure in Ontario has been escalating at increasing rates and a growing proportion of this has come from medical devices and other technologies. A comprehensive evidence-based process for the assessment of new health technologies in Ontario was recently established (the Health...
Persistent link: https://www.econbiz.de/10005449095
This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as...
Persistent link: https://www.econbiz.de/10005590453
The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....
Persistent link: https://www.econbiz.de/10005449189
In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method for valuing benefits in a CBA and describe how to obtain willingness-to-pay (WTP) measures of health benefits...
Persistent link: https://www.econbiz.de/10005449256
Persistent link: https://www.econbiz.de/10005404902
DOI: 10.2165/0019053-200826100-00009
Persistent link: https://www.econbiz.de/10004997788
DOI: 10.2165/0019053-200826100-00008
Persistent link: https://www.econbiz.de/10005590278